JP2021518361A5 - - Google Patents
Info
- Publication number
- JP2021518361A5 JP2021518361A5 JP2020549641A JP2020549641A JP2021518361A5 JP 2021518361 A5 JP2021518361 A5 JP 2021518361A5 JP 2020549641 A JP2020549641 A JP 2020549641A JP 2020549641 A JP2020549641 A JP 2020549641A JP 2021518361 A5 JP2021518361 A5 JP 2021518361A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024159928A JP2024163336A (ja) | 2018-03-16 | 2024-09-17 | アンチセンス送達用キメラペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644202P | 2018-03-16 | 2018-03-16 | |
| US62/644,202 | 2018-03-16 | ||
| PCT/US2019/022475 WO2019178479A1 (en) | 2018-03-16 | 2019-03-15 | Chimeric peptides for antisense delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159928A Division JP2024163336A (ja) | 2018-03-16 | 2024-09-17 | アンチセンス送達用キメラペプチド |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518361A JP2021518361A (ja) | 2021-08-02 |
| JP2021518361A5 true JP2021518361A5 (https=) | 2023-08-28 |
| JPWO2019178479A5 JPWO2019178479A5 (https=) | 2023-08-28 |
| JP7596148B2 JP7596148B2 (ja) | 2024-12-09 |
Family
ID=67908050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549641A Active JP7596148B2 (ja) | 2018-03-16 | 2019-03-15 | アンチセンス送達用キメラペプチド |
| JP2024159928A Pending JP2024163336A (ja) | 2018-03-16 | 2024-09-17 | アンチセンス送達用キメラペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159928A Pending JP2024163336A (ja) | 2018-03-16 | 2024-09-17 | アンチセンス送達用キメラペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12370261B2 (https=) |
| EP (1) | EP3765030A4 (https=) |
| JP (2) | JP7596148B2 (https=) |
| MA (1) | MA52148A (https=) |
| TW (1) | TW202002990A (https=) |
| WO (1) | WO2019178479A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| WO2021150867A1 (en) * | 2020-01-24 | 2021-07-29 | Sarepta Therapeutics, Inc. | Designing antisense oligonucleotide delivery peptides by interpretable machine learning |
| CA3211038A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| WO2026080471A2 (en) | 2024-10-07 | 2026-04-16 | Flagship Pioneering Innovations Vi, Llc | Compositions of trem conjugates and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6784291B2 (en) | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| CA2614191C (en) | 2005-07-13 | 2015-06-30 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| DK2735568T3 (da) | 2006-05-10 | 2017-11-13 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske bindinger mellem underenheder |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US8575305B2 (en) * | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
| WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
| WO2013017631A1 (en) | 2011-08-04 | 2013-02-07 | Msd Oss B.V. | Kisspeptide-pentasaccharide conjugates |
| KR102451116B1 (ko) * | 2011-10-27 | 2022-10-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| KR102240217B1 (ko) | 2012-09-25 | 2021-04-14 | 젠자임 코포레이션 | 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드 |
| WO2014124952A1 (en) | 2013-02-12 | 2014-08-21 | Syddansk Universitet | "clickable" alkyne-lna oligonucleotides |
| RS58529B1 (sr) | 2013-03-14 | 2019-04-30 | Sarepta Therapeutics Inc | Sastavi koji preskaču egzon za tretiranje mišićne distrofije |
| CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| US11371994B2 (en) | 2013-09-13 | 2022-06-28 | California Institute Of Technology | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making |
| SG10201811729PA (en) * | 2013-12-12 | 2019-02-27 | Life Technologies Corp | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| GB201421379D0 (en) | 2014-12-02 | 2015-01-14 | Isis Innovation Ltd And Medical Res Council | Molecule |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| EP3829597A4 (en) * | 2018-07-30 | 2022-05-18 | Sarepta Therapeutics, Inc. | TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION |
-
2019
- 2019-03-15 MA MA052148A patent/MA52148A/fr unknown
- 2019-03-15 TW TW108108833A patent/TW202002990A/zh unknown
- 2019-03-15 WO PCT/US2019/022475 patent/WO2019178479A1/en not_active Ceased
- 2019-03-15 US US16/981,145 patent/US12370261B2/en active Active
- 2019-03-15 JP JP2020549641A patent/JP7596148B2/ja active Active
- 2019-03-15 EP EP19767585.3A patent/EP3765030A4/en active Pending
-
2024
- 2024-09-17 JP JP2024159928A patent/JP2024163336A/ja active Pending
-
2025
- 2025-06-10 US US19/233,984 patent/US20250367306A1/en active Pending